{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T21:06:04Z","timestamp":1783199164171,"version":"3.54.6"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Despite the various initiatives carried out in Brazil and in the world, the challenge of offering essential medicines in adequate presentations remains, especially to the public affected by diseases considered neglected and the pediatric population, for whom the therapeutic options remain limited. The main objective of this study was to evaluate the production of manipulated medicines as a strategy to mitigate therapeutic and access gaps to essential medicines within the Brazilian public health system, called the Unified Health System (SUS). The evaluation, carried out between 2020 and 2021, identified, among the medicines considered essential to the Brazilian health context, those unavailable, for which strategies were evaluated to mitigate the identified unavailability, which is conventionally called therapeutic gaps. For 57% (n = 235) of pharmaceutical presentations identified as therapeutic gaps in SUS, manipulation was identified as the best strategy to promote access. Of these presentations, 30% (n = 70) were identified as priorities in the context of patient care and were mainly related to the demands of the pediatric public and those affected by poverty-related diseases. Concerning poverty-related diseases, the absence of evidence on the development of a standard formula for drugs with indication for such diseases was demonstrated. The need for an annual investment of approximately US$74.75 per capita was estimated to offer treatments in adequate presentations to SUS users, which should reflect in the improvement of the quality of life of about 26 thousand people. It was observed that this investment amount corresponds to only 3% of the budget for the purchase of medicines financed exclusively by the Ministry of Health thorugh the Strategic Component of Pharmaceutical Assistance (CESAF) approved for 2021.<\/jats:p>","DOI":"10.1371\/journal.pone.0276785","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T18:43:02Z","timestamp":1668019382000},"page":"e0276785","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Medicine manipulation: An alternative to mitigate therapeutic gaps in the Brazilian Unified Health System?"],"prefix":"10.1371","volume":"17","author":[{"given":"Gabriel Gon\u00e7alves","family":"Okamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5131-5297","authenticated-orcid":true,"given":"Kathiely Martins","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luma de Lira","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Martins","family":"Gelfuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4481-210X","authenticated-orcid":true,"given":"Rafael Santos","family":"Santana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"issue":"5","key":"pone.0276785.ref001","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1590\/1413-81232017225.32762016","article-title":"Registro e incorpora\u00e7\u00e3o de tecnologias no SUS: barreiras de acesso a medicamento.s para doen\u00e7as da pobreza?","volume":"22","author":"RS Santana","year":"2017","journal-title":"Ci\u00eancia e Sa\u00fade Coletiva"},{"issue":"10","key":"pone.0276785.ref002","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1590\/S0100-40422013001000011","article-title":"Doen\u00e7as tropicais negligenciadas: uma nova era de desafios e oportunidades","volume":"36","author":"LC Dias","year":"2013","journal-title":"Quim Nova"},{"key":"pone.0276785.ref003","unstructured":"OMS. Primeiro relat\u00f3rio da OMS sobre doen\u00e7as tropicais negligenciadas: Avan\u00e7os para superar o impacto global de doen\u00e7as tropicais negligenciadas. 2012, 172 p."},{"key":"pone.0276785.ref004","unstructured":"Petroni MF. Formas Farmac\u00eauticas em Pediatria: um desafio. Revista F\u00e1rmacos e Medicamentos. 2011; 38\u201341."},{"issue":"3","key":"pone.0276785.ref005","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2710.2008.01005.x","article-title":"Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature","volume":"34","author":"L. Lindell-Osuagwu","year":"2009","journal-title":"Journal of clinical pharmacy and therapeutics"},{"issue":"1","key":"pone.0276785.ref006","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/ped.12190","article-title":"Off-label and unlicensed drug use among neonatal intensive care units in Southern Italy","volume":"56","author":"N Laforgia","year":"2014","journal-title":"Pediatrics International"},{"issue":"2","key":"pone.0276785.ref007","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/ped.12771","article-title":"Off-label and unlicensed use of medicinal products in the neonatal setting in the Slovak Republic","volume":"58","author":"J. Schweigertova","year":"2016","journal-title":"Pediatrics International"},{"issue":"2\u20133","key":"pone.0276785.ref008","first-page":"75","article-title":"Medicamentos manipulados em pediatria: estado actual e perspectivas futuras","volume":"22","author":"S Pinto","year":"2008","journal-title":"Arquivos de Medicina"},{"key":"pone.0276785.ref009","first-page":"74","volume-title":"Manipula\u00e7\u00e3o de medicamentos necess\u00e1rios para crian\u00e7as: um guia para profissionais de sa\u00fade","author":"C Barker","year":"2018"},{"issue":"2","key":"pone.0276785.ref010","doi-asserted-by":"crossref","first-page":"266","DOI":"10.5935\/0103-507X.20210034","article-title":"Prescription of off-label and unlicensed drugs for preterm infants in a neonatal intensive care unit","volume":"33","author":"VC Vieira","year":"2021","journal-title":"Revista Brasileira de Terapia Intensiva"},{"key":"pone.0276785.ref011","unstructured":"Access to Medicine Foundation. Closing gaps in access to medicine for children: how R & D and delivery efforts can be ramped up. 2021;1\u20134. ttps:\/\/accesstomedicinefoundation.org\/media\/uploads\/downloads\/6078436950e68_ATMI_Paediatric_Finding_2021.pdf"},{"issue":"1","key":"pone.0276785.ref012","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1590\/S1020-49892010000100007","article-title":"Fundo Estrat\u00e9gico da Organiza\u00e7\u00e3o Pan-Americana da Sa\u00fade: mecanismo facilitador para melhorar o acesso aos medicamentos","volume":"27","author":"MMLL Horst","year":"2010","journal-title":"Revista Panamericana de Salud P\u00fablica"},{"key":"pone.0276785.ref013","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Assist\u00eancia Farmac\u00eautica em Pediatria no Brasil: recomenda\u00e7\u00f5es e estrat\u00e9gias para a amplia\u00e7\u00e3o da oferta, do acesso e do uso racional de medicamentos em crian\u00e7as. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade. 2017;82 p. ISBN 978-85-334-2467-8."},{"key":"pone.0276785.ref014","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Secretaria de Ci\u00eancia, Tecnologia, Inova\u00e7\u00e3o e Insumos Estrat\u00e9gicos em Sa\u00fade. Departamento de Assist\u00eancia Farmac\u00eautica e Insumos Estrat\u00e9gicos. Rela\u00e7\u00e3o Nacional de Medicamentos Essenciais: Rename 2020. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade, 2020;217 p. https:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/relacao_medicamentos_rename_2020.pdf"},{"key":"pone.0276785.ref015","first-page":"119","article-title":"World health organization model list of essential medicines","volume":"21","author":"World Health Organization","year":"2019","journal-title":"Mental and Holistic Health: Some International Perspectives"},{"key":"pone.0276785.ref016","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade Secretaria de Ci\u00eancia, Tecnologia e Insumos Estrat\u00e9gicos. Departamento de Assist\u00eancia Farmac\u00eautica e Insumos Estrat\u00e9gicos. Formul\u00e1rio terap\u00eautico nacional 2010: Rename 2010. 2. ed. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade, 2010. 1135 p. https:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/formulario_terapeutico_nacional_2010.pdf"},{"key":"pone.0276785.ref017","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Secretaria de Vigil\u00e2ncia em Sa\u00fade. Coordena\u00e7\u00e3o-Geral de Desenvolvimento da Epidemiologia em Servi\u00e7os. Guia de Vigil\u00e2ncia em Sa\u00fade. 3. ed. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade, 2019."},{"key":"pone.0276785.ref018","unstructured":"Darasus, Departamento de Inform\u00e1tica do SUS. MedSus. Vers\u00e3o 0.0.5 \u2013Android; Vers\u00e3o 1.3 \u2013iOS [Aplicativo para dispositivos m\u00f3veis], c2014."},{"key":"pone.0276785.ref019","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. ANVISA, 2021. C\u00e2mara de Regula\u00e7\u00e3o do Mercado de Medicamentos (CMED). https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/medicamentos\/cmed"},{"key":"pone.0276785.ref020","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. ANVISA, 2021. Consultas. https:\/\/consultas.anvisa.gov.br\/#\/medicamentos"},{"key":"pone.0276785.ref021","unstructured":"Brasil. Lei n\u00ba 12.527, de 18 de novembro de 2011. Lei do acesso \u00e0 informa\u00e7\u00e3o. http:\/\/www.planalto.gov.br\/ccivil_03\/_ato2011-2014\/2011\/lei\/l12527.htm"},{"key":"pone.0276785.ref022","unstructured":"Brasil. Farmacopeia Brasileira. 6th Edition, Vol 1. Anvisa. 2019;1:874."},{"key":"pone.0276785.ref023","unstructured":"USP. Farmacopeia dos Estados Unidos e Formul\u00e1rio Nacional. USP 34 NF.; 2011."},{"key":"pone.0276785.ref024","first-page":"728","volume-title":"Prepara\u00e7\u00f5es Ora\u00e7\u00f5es L\u00edquidas","author":"AO Ferreira","year":"2011","edition":"3"},{"key":"pone.0276785.ref025","author":"JAO Batistuzzo","year":"2015","journal-title":"Formul\u00e1rio M\u00e9dico Farmac\u00eautico. 5. ed. S\u00e3o Paulo: Atheneu"},{"key":"pone.0276785.ref026","unstructured":"Souza GB. Formul\u00e1rio Terap\u00eautico em Pediatria. Editora Associados HPC, 2021."},{"key":"pone.0276785.ref027","unstructured":"Ferreira AO, Polonini HC, Lima LC. Formula\u00e7\u00f5es l\u00edquidas de uso oral. Editora Associada, 2019."},{"key":"pone.0276785.ref028","unstructured":"Anfarmag. S\u00e9rie: Prepara\u00e7\u00f5es orais l\u00edquidas: aspectos farmacot\u00e9cnicos da prepara\u00e7\u00e3o oral l\u00edquida pedi\u00e1trica. 5\u00ba informe."},{"key":"pone.0276785.ref029","unstructured":"Santos CSF. Medicamentos manipulados pedi\u00e1tricos: desenvolvimento de formula\u00e7\u00f5es de ranidina e clindamicina. 2011. 81 p. Disserta\u00e7\u00e3o (Mestrado em Ci\u00eancias Farmac\u00eauticas)\u2013Faculdade de Ci\u00eancias da Sa\u00fade, Universidade Fernando Pessoa, Porto, Portugal, 2011."},{"key":"pone.0276785.ref030","unstructured":"Brasil. Minist\u00e9rio da Economia. Painel de pre\u00e7o. https:\/\/paineldeprecos.planejamento.gov.br"},{"key":"pone.0276785.ref031","unstructured":"Brasil. Minist\u00e9rio do Planejamento, Desenvolvimento e Gest\u00e3o. Portal de compras. https:\/\/www.gov.br\/compras\/pt-br"},{"key":"pone.0276785.ref032","unstructured":"Ta H, Ca J. An\u00e1lise de viabilidade. Anfarmag. 2004;(2049842):2004\u20132005."},{"key":"pone.0276785.ref033","unstructured":"Michels A, Sott VR, Santos GKA, Moser M. Forma\u00e7\u00e3o do pre\u00e7o de venda: estudo de caso em uma farm\u00e1cia de manipula\u00e7\u00e3o. Anais do Congresso Brasileiro de Custos\u2013ABC. 2017. https:\/\/anaiscbc.emnuvens.com.br\/anais\/article\/view\/4358"},{"key":"pone.0276785.ref034","unstructured":"Geral R, Or\u00e7ament\u00e1ria P, Meta TS. Congresso Nacional\u2014Comiss\u00e3o Mista de Plano, Or\u00e7amentos P\u00fablicos e Fiscaliza\u00e7\u00e3o Congresso Nacional\u2014Comiss\u00e3o Mista de Planos, Or\u00e7amentos P\u00fablicos e Fiscaliza\u00e7\u00e3o Relatoria Geral\u2014Altera\u00e7\u00f5es da Proposta Or\u00e7ament\u00e1ria da Uni\u00e3o para 2021. 2021:39\u201341."},{"key":"pone.0276785.ref035","unstructured":"Brasil. Lei n\u00ba 14.144, de 22 de abril de 2021. Estima a receita e fixa a despesa da Uni\u00e3o para o exerc\u00edcio financeiro de 2021. Bras\u00edlia\u2013DF: Presid\u00eancia da Rep\u00fablica, 2021. http:\/\/www.planalto.gov.br\/ccivil_03\/_ato2019-2022\/2021\/lei\/L14144.htm"},{"issue":"10","key":"pone.0276785.ref036","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00228-002-0554-2","article-title":"Sturkenboom MCJM, Van Den Anker JN, Stricker BHC. Determinants for drug prescribing to children below the minimum licensed age","volume":"58","author":"GW T Jong","year":"2003","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"1","key":"pone.0276785.ref037","first-page":"72","article-title":"Utiliza\u00e7\u00e3o da hidroxiur\u00e9ia em paciente com anemia falciforme: estudo de caso","volume":"5","author":"DS Colombo","year":"2012","journal-title":"Revista Educa\u00e7\u00e3o, Meio Ambiente e Sa\u00fade"},{"key":"pone.0276785.ref038","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Resolu\u00e7\u00e3o\u2013RDC n\u00ba 67, de 8 de outubro de 2007. https:\/\/bvsms.saude.gov.br\/bvs\/saudelegis\/anvisa\/2007\/rdc0067_08_10_2007.html"},{"issue":"2","key":"pone.0276785.ref039","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1590\/1414-462x201700020272","article-title":"Produ\u00e7\u00e3o e avalia\u00e7\u00e3o comparativa de pre\u00e7os de produtos do Laborat\u00f3rio de Manipula\u00e7\u00e3o Farmac\u00eautica\u2014Ribeir\u00e3o Preto\u2013SP: experi\u00eancia relacionada \u00e0 Assist\u00eancia Farmac\u00eautica no SUS","volume":"25","author":"JC Borella","year":"2017","journal-title":"Cadernos Sa\u00fade Coletiva"},{"issue":"4","key":"pone.0276785.ref040","first-page":"403","article-title":"Medicamentos magistrais em rec\u00e9m\u2010nascidos e crian\u00e7as hospitalizados","volume":"34","author":"ACS Pereira","year":"2016","journal-title":"Revista Paulista de Pediatria"},{"issue":"1","key":"pone.0276785.ref041","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1590\/S0104-42302012000100019","article-title":"A alta preval\u00eancia de prescri\u00e7\u00f5es de medicamentos off-label e n\u00e3o licenciados em unidade de terapia intensiva pedi\u00e1trica brasileira","volume":"58","author":"LA Ferreira","year":"2012","journal-title":"Revista da Associac\u00e3o M\u00e9dica Brasileira"},{"issue":"1","key":"pone.0276785.ref042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-017-0741-y","article-title":"Compounded medication for patients with rare diseases","volume":"13","author":"M Dooms","year":"2018","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"pone.0276785.ref043","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41587-019-0044-z","article-title":"Magistral drug production in Colombia and other middle-income countries","volume":"37","author":"CP Vaca Gonz\u00e1lez","year":"2019","journal-title":"Nat. Biotechnol"},{"key":"pone.0276785.ref044","unstructured":"Nogueira M, Balteiro J, Rocha C, Rodrigues V. Medicamentos manipulados em farm\u00e1cias comunit\u00e1rias: que realidade? In: VI Encontro Nacional das Ci\u00eancias e Tecnologias da Sa\u00fade, ESTeSL, 20\u201322 Oct 2011. https:\/\/repositorio.ipl.pt\/bitstream\/10400.21\/1058\/1\/Medicamentos%20manipulados%20em%20farm%c3%a1cias%20comunit%c3%a1rias.pdf"},{"key":"pone.0276785.ref045","unstructured":"Anfarmag. Panorama 2020\u2014Dados socioecon\u00f4micos das farm\u00e1cias de manipula\u00e7\u00e3o. S\u00e3o Paulo: 2020. https:\/\/www.anfarmag.org.br\/panorama-setorial-anfarmag"},{"issue":"2","key":"pone.0276785.ref046","first-page":"184","article-title":"An\u00e1lise dos consumidores de drogarias e farm\u00e1cias e \u00edndice de aceita\u00e7\u00e3o dos medicamentos manipulados na cidade de S\u00e3o Francisco de Assis, RS","volume":"94","author":"AL Gindri","year":"2013","journal-title":"Revista Brasileira de Farm\u00e1cia"},{"issue":"11\/12","key":"pone.0276785.ref047","first-page":"3","article-title":"\u00cdndice de aceita\u00e7\u00e3o de medicamentos manipulados, no munic\u00edpio de Cacoal\u2013RO","volume":"20","author":"JA Alves","year":"2013","journal-title":"Infarma"},{"issue":"4","key":"pone.0276785.ref048","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/ijpp.12455","article-title":"Assessment tool for establishing local pharmaceutical manufacturing in low- and middle-income countries","volume":"26","author":"M Zimmermann","year":"2018","journal-title":"Int J Pharm Pract"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0276785","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T18:43:33Z","timestamp":1668019413000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0276785"}},"subtitle":[],"editor":[{"given":"Paola","family":"Brusa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":48,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0276785","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,9]]}}}